Comparative Pharmacology
Head-to-head clinical analysis: AXUMIN versus DRAXIMAGE MDP 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXUMIN versus DRAXIMAGE MDP 10.
AXUMIN vs DRAXIMAGE MDP-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor; inhibits VEGFR-1, -2, -3, and PDGFR-β, Kit, and RET.
Technetium-99m medronate is a bone-seeking radiopharmaceutical that localizes in areas of bone turnover, binding via chemisorption to hydroxyapatite crystals, allowing scintigraphic imaging of skeletal lesions.
AXUMIN (florbetaben F 18) is a diagnostic radiopharmaceutical for PET imaging of beta-amyloid plaques. The recommended dose is 300 MBq (8.1 mCi) administered as a single intravenous bolus injection over 10-15 seconds, followed by a saline flush.
555-1110 MBq (15-30 mCi) intravenously for skeletal imaging; administered 2-3 hours before imaging.
None Documented
None Documented
The terminal elimination half-life is approximately 2.7 hours (range 1.5-5.0 hours) in patients with normal renal function; this supports twice-daily dosing, but may be prolonged in renal impairment.
Terminal elimination half-life: 2.5 hours (range 2-3 hours); clinically, allows rapid imaging post-injection.
Renal elimination of unchanged drug accounts for approximately 60% of the administered dose; fecal excretion accounts for approximately 35% (mainly as unchanged drug); biliary excretion contributes to fecal elimination; less than 1% is excreted in urine as metabolites.
Renal: 95% within 6 hours; biliary/fecal: <5%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical